MedTrace Logo

Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

NCT05170048 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-12-08

No results posted yet for this study

Summary

This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD).

Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are:

1. AREDS2 supplements (Control Group, N=30)
2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)

Conditions

  • Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)

Interventions

DRUG

EG-301

The investigation drug, EG-301 Tablets 150mg, is for oral use.

DIETARY_SUPPLEMENT

AREDS2 supplements

AREDS2 supplement is the stand of care

Sponsors & Collaborators

  • Evergreen Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170048 on ClinicalTrials.gov